

TAP2 Antibody

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 72	Source/Isotype: Rabbit	UniProt ID: #Q03519	Entrez-Gene Id: 6891
-------------------------------	-------------------------	-----------------------------------	------------------------	----------------------------------	-------------------------------	--------------------------------

Product Usage Information**Application**

Western Blotting
Immunoprecipitation

Dilution

1:1000
1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

TAP2 Antibody recognizes endogenous levels of total TAP2 protein.

Species predicted to react based on 100% sequence homology

Monkey

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe588 of human TAP2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CD8⁺ cytotoxic T cells recognize peptides presented by MHC class I molecules on the surface of infected cells and tumor cells. The transporters associated with antigen processing 1 and 2 (TAP1 and TAP2) form the TAP complex which resides on the ER membrane and transports peptides from the cytoplasm into the ER for loading onto MHC class I molecules (1-8). In addition, TAP localized to endosomal membranes is important for cross-presentation by dendritic cells (9,10). IFN-γ produced by T cells and NK cells in response to infection causes upregulation of TAP1 and TAP2, resulting in increased antigen presentation to T cells (11). Some viral proteins inhibit TAP function or downregulate TAP expression resulting in viral immune evasion (12,13). In addition, investigators have observed reduced TAP expression in a variety of tumor types, and it is thought to be one mechanism for tumor immune evasion (14).

Background References

1. Trowsdale, J. et al. (1990) *Nature* 348, 741-4.
2. Spies, T. et al. (1990) *Nature* 348, 744-7.
3. Deverson, E.V. et al. (1990) *Nature* 348, 738-41.
4. Monaco, J.J. et al. (1990) *Science* 250, 1723-6.
5. Spies, T. and DeMars, R. (1991) *Nature* 351, 323-4.
6. Kleijmeer, M.J. et al. (1992) *Nature* 357, 342-4.
7. Kelly, A. et al. (1992) *Nature* 355, 641-4.
8. Spies, T. et al. (1992) *Nature* 355, 644-6.
9. Huang, A.Y. et al. (1996) *Immunity* 4, 349-55.
10. Guernonprez, P. et al. (2003) *Nature* 425, 397-402.
11. Bahram, S. et al. (1991) *Proc Natl Acad Sci U S A* 88, 10094-8.
12. Früh, K. et al. (1995) *Nature* 375, 415-8.
13. Bennett, E.M. et al. (1999) *J Immunol* 162, 5049-52.
14. Steer, H.J. et al. (2010) *Oncogene* 29, 6301-13.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.